Tumor Immunology and Immunotherapy by Robert C. ReesTumor Immunology and Immunotherapy by Robert C. Rees

Tumor Immunology and Immunotherapy

EditorRobert C. Rees

Hardcover | June 27, 2014

Pricing and Purchase Info


Earn 1,175 plum® points

Prices and offers may vary in store


Ships within 1-3 weeks

Ships free on orders over $25

Not available in stores


Patients are beginning to benefit from antibody based, cellular and vaccine approaches that are effective against genetically diverse and therapy-resistance cancers. BCG immunotherapy is now being used as a first line treatment for human bladder cancer and the introduction of prophylacticvaccination against Hepatitis B and HPV cancers is starting to show positive results. Following recent FDA approval for a vaccination against prostate cancer, and optimistic results in clinical trials for a vaccine targeting cancer antigens in lung cancer, cancer immunotherapy is now significantlyimpacting patient clinical management.Tumor Immunology and Immunotherapy provides an up-to-date and comprehensive account of cancer immunity and immunotherapy. It discusses our adaptive and innate immunity to cancer, the mechanisms underpinning our immune response, current approaches to cancer immunotherapy, and how tumour and hostresponses can circumvent effective anti-cancer immunity.The book examines recent results, publications and current areas of interest including "immune editing" and the specific issues that are affecting the research and development of vaccines, providing insight into how these problems may be overcome, as viewed by world leaders in the field. TumorImmunology and Immunotherapy will appeal to clinicians working in oncology and cancer immunotherapy, and research scientists including PhD and masters students, post-doctoral researchers and senior investigators.
Robert C. Rees is Director and Professor of Tumour Biology at The John van Geest Cancer Research Centre at Nottingham Trent University, Nottingham, UK.
Title:Tumor Immunology and ImmunotherapyFormat:HardcoverDimensions:496 pages, 9.69 × 6.73 × 0 inPublished:June 27, 2014Publisher:Oxford University PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0199676860

ISBN - 13:9780199676866


Table of Contents

1. Pedro Romero and Pierre G. Coulie: Adaptive T-cell immunity and tumor antigen recognition2. Gail D. Sckisel, Arta M. Monjazeb, Annie Mirsoian, Anthony E. Zamora, Steven Grossenbacher, and William J. Murphy: Impact of aging and body mass on cancer immunotherapy outcomes3. Thomas C.C. Tan, Jean-Marc Doisne and Francesco Colucci: The potential of natural killer cells in cancer immunotherapy4. Russell Hughes and Munitta Muthana: The tumour microenvironment: the role of tumour associated macrophages in cancer progression and responses to therapy5. Natalia Aptsiauri, Angel M. Garcia-Lora, Federico Garrido: "Hard" and "soft" loss of MHC class I expression in cancer cells6. A.G. Dalgleish: Modulation of the adaptive immune system through chronic inflammation and T-regulatory responses7. Pratima Sinha, Virginia Clements, Meghan Burke, Catherine Fenselau, and Suzanne Ostrand-Rosenberg: Myeloid-derived suppressor cells: immune suppressive cells that facilitate tumor progression and promote and deter cancer-associated inflammation.8. Thomas J. Sayers and Neil A Cross: Triggering death receptors as a means of inducing tumoricidal activity9. Jayakumar Vadakekolathu, Stephanie B. McArdle, David J. Boocock, and Amanda Miles: Identification of tumor antigens for clinical evaluation10. Peter L. Stern and Kenneth Oguejiofor: Viral antigens as targets for prophylactic and therapeutic intervention in cancer11. Constantin N. Baxevanis and Sonia A. Perez: HER-2/neu as a target for vaccine and antibody directed therapies12. Matteo Bellone, Sara Martina Parigi, and Elena Jachetti: Pre-clinical evaluation of immunotherapy: the case for prostate cancer and the tramp model13. Per thor Straten, Dave Schrama, Jurgen C. Becker and Mads Hald Andersen: Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy14. M. Strioga and E. Tartour: Predictive biomarkers to better select patients for cancer immunotherapy15. Karishma Rajani, Vanessa Alonso-Camino, Nicolas Boisgerault, Richard Vile: Viral platforms for expression of tumour antigens in cancer immunotherapy16. Paul Moss: Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies17. L. G. Durrant, W. Xue, L. R. Machado, R. L. Metheringham, and V. A. Brentville: DNA vaccines18. Uzoma K. Iheagwaraa, Pamela L. Beattya, Chan Su-Wan Biancaa, Lora H. Rigattid, Ted Ross, and Olivera J. Finn: Programming the immune system through childhood infections: MUC1 Tumor Associated Antigen (TAA) as a Disease Associated Antigen (DAA)19. Susanne Hofmann, Ghazala Khan, Viktoriya Boncheva, Jochen Greiner, and Barbara-Ann Guinn: Vaccination against myeloid leukaemias using newly defined antigens20. Patrick A. Ott and F. Stephen Hodi: Immune-checkpoint blockade in cancer immunotherapy21. Harpreet Singh-Jasuja, Toni Weinschenk, and Steffen Walter: Multi-peptide cancer vaccines for clinical application22. Marco Donia, Eva Ellebaek, and Inge Marie Svane: Adoptive T-cell therapy using TILs for the treatment of metastatic melanoma23. John S. Bridgeman and David E. Gilham: Chimeric antigen receptor gene therapy in cancer24. Claire Deligne, Sophie Siberil, and Jean-Luc Teillaud: The vaccinal effect of monoclonal antibodies in cancer therapy25. Gabriele Multhoff and Michael Stanglmaier: Antibody therapies: defining appropriate cell surface epitopes for targeting tumours26. Sophie Derniame and Aurore Saudemont: Adoptive lymphocyte (stem cell) therapy in cancer27. Tarik Regad and Morgan G. Mathieu: Cancer Stem Cells (CSCs) and Epithelial-to-Mesenchymal Transition (EMT): Tumor Cell Plasticity Challenges Immunotherapy28. Ludmila Muller and Graham Pawelec: Immune escape and aging of the immune system compromises the immune response to tumor antigens